PubRank

Cem Akin

Author PubWeight™ 56.00‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Mast Cells, Mastocytosis, and Related Disorders. N Engl J Med 2015 3.90
2 Characterization of novel stem cell factor responsive human mast cell lines LAD 1 and 2 established from a patient with mast cell sarcoma/leukemia; activation following aggregation of FcepsilonRI or FcgammaRI. Leuk Res 2003 3.00
3 Elevated serum tryptase levels identify a subset of patients with a myeloproliferative variant of idiopathic hypereosinophilic syndrome associated with tissue fibrosis, poor prognosis, and imatinib responsiveness. Blood 2003 2.61
4 The c-KIT mutation causing human mastocytosis is resistant to STI571 and other KIT kinase inhibitors; kinases with enzymatic site mutations show different inhibitor sensitivity profiles than wild-type kinases and those with regulatory-type mutations. Blood 2002 2.39
5 Definitions, criteria and global classification of mast cell disorders with special reference to mast cell activation syndromes: a consensus proposal. Int Arch Allergy Immunol 2011 1.63
6 Mastocytosis: pathology, genetics, and current options for therapy. Leuk Lymphoma 2005 1.61
7 Dasatinib (BMS-354825) inhibits KITD816V, an imatinib-resistant activating mutation that triggers neoplastic growth in most patients with systemic mastocytosis. Blood 2006 1.55
8 Diagnosis and treatment of systemic mastocytosis: state of the art. Br J Haematol 2003 1.54
9 The identification and characterisation of novel KIT transcripts in aggressive mast cell malignancies and normal CD34+ cells. Leuk Lymphoma 2008 1.44
10 Aggressive systemic mastocytosis and related mast cell disorders: current treatment options and proposed response criteria. Leuk Res 2003 1.39
11 Phase II study of dasatinib in Philadelphia chromosome-negative acute and chronic myeloid diseases, including systemic mastocytosis. Clin Cancer Res 2008 1.39
12 Molecular remission and reversal of myelofibrosis in response to imatinib mesylate treatment in patients with the myeloproliferative variant of hypereosinophilic syndrome. Blood 2003 1.37
13 KIT D816V-associated systemic mastocytosis with eosinophilia and FIP1L1/PDGFRA-associated chronic eosinophilic leukemia are distinct entities. J Allergy Clin Immunol 2007 1.33
14 17-Allylamino-17-demethoxygeldanamycin (17-AAG) is effective in down-regulating mutated, constitutively activated KIT protein in human mast cells. Blood 2003 1.32
15 Evidence for the involvement of a hematopoietic progenitor cell in systemic mastocytosis from single-cell analysis of mutations in the c-kit gene. Blood 2002 1.09
16 Mast cell activation syndrome: a newly recognized disorder with systemic clinical manifestations. J Allergy Clin Immunol 2011 1.07
17 How I treat patients with advanced systemic mastocytosis. Blood 2010 1.06
18 Tyrosine kinase inhibitors in the treatment of systemic mastocytosis. Leuk Res 2011 1.05
19 EXEL-0862, a novel tyrosine kinase inhibitor, induces apoptosis in vitro and ex vivo in human mast cells expressing the KIT D816V mutation. Blood 2006 1.04
20 A clinicopathologic study of 24 cases of systemic mastocytosis involving the gastrointestinal tract and assessment of mucosal mast cell density in irritable bowel syndrome and asymptomatic patients. Am J Surg Pathol 2014 1.03
21 Mast cell proliferative disorders: current view on variants recognized by the World Health Organization. Hematol Oncol Clin North Am 2003 1.01
22 International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) & European Competence Network on Mastocytosis (ECNM) consensus response criteria in advanced systemic mastocytosis. Blood 2013 1.01
23 Current options in the treatment of mast cell mediator-related symptoms in mastocytosis. Inflamm Allergy Drug Targets 2006 1.00
24 Assessment of the extent of cutaneous involvement in children and adults with mastocytosis: relationship to symptomatology, tryptase levels, and bone marrow pathology. J Am Acad Dermatol 2003 0.99
25 Activity of imatinib in systemic mastocytosis with chronic basophilic leukemia and a PRKG2-PDGFRB fusion. Haematologica 2008 0.96
26 Levels of mast-cell growth factors in plasma and in suction skin blister fluid in adults with mastocytosis: correlation with dermal mast-cell numbers and mast-cell tryptase. J Allergy Clin Immunol 2002 0.93
27 Effects of AMN107, a novel aminopyrimidine tyrosine kinase inhibitor, on human mast cells bearing wild-type or mutated codon 816 c-kit. Leuk Res 2006 0.91
28 Mastocytosis: update on pharmacotherapy and future directions. Expert Opin Pharmacother 2013 0.91
29 Regression of urticaria pigmentosa in adult patients with systemic mastocytosis: correlation with clinical patterns of disease. Arch Dermatol 2002 0.91
30 The classification of systemic mastocytosis should include mast cell leukemia (MCL) and systemic mastocytosis with a clonal hematologic non-mast cell lineage disease (SM-AHNMD). Blood 2010 0.86
31 IL-6 levels predict disease variant and extent of organ involvement in patients with mastocytosis. Clin Immunol 2005 0.86
32 Mast cell sarcoma: a rare and potentially under-recognized diagnostic entity with specific therapeutic implications. Mod Pathol 2012 0.86
33 Thrombopoietin alone or in the presence of stem cell factor supports the growth of KIT(CD117)low/ MPL(CD110)+ human mast cells from hematopoietic progenitor cells. Exp Hematol 2005 0.84
34 Demonstration that mast cells, T cells, and B cells bearing the activating kit mutation D816V occur in clusters within the marrow of patients with mastocytosis. J Mol Diagn 2004 0.84
35 Primary mast cell disorders in children. Curr Allergy Asthma Rep 2013 0.83
36 Mastocytosis and allergy. Curr Opin Allergy Clin Immunol 2007 0.83
37 The serum tryptase test: an emerging robust biomarker in clinical hematology. Expert Rev Hematol 2014 0.83
38 Analysis of the lineage relationship between mast cells and basophils using the c-kit D816V mutation as a biologic signature. J Allergy Clin Immunol 2005 0.82
39 Gene expression analysis in mastocytosis reveals a highly consistent profile with candidate molecular markers. J Allergy Clin Immunol 2003 0.81
40 Mastocytosis: advances in diagnosis and treatment. Curr Allergy Asthma Rep 2007 0.81
41 Elevated tryptase levels are associated with greater bone density in a cohort of patients with mastocytosis. Int Arch Allergy Immunol 2006 0.80
42 Tryptase is not cleared by the kidneys into the urine. Int Arch Allergy Immunol 2009 0.79
43 Smouldering mastocytosis: a novel subtype of systemic mastocytosis with slow progression. Int Arch Allergy Immunol 2002 0.79
44 Mast cells and eosinophils in mastocytosis, chronic eosinophilic leukemia, and non-clonal disorders. Semin Hematol 2012 0.79
45 Lenalidomide therapy in systemic mastocytosis. Leuk Res 2008 0.78
46 Generalized erythematous macules and plaques associated with flushing, repeated syncope, and refractory anemia. J Am Acad Dermatol 2002 0.77
47 Mast Cells, Mastocytosis, and Related Disorders. N Engl J Med 2015 0.77
48 Refinements in response criteria in systemic mastocytosis: reply to a proposal. Eur J Haematol 2010 0.75
49 Multilineage hematopoietic involvement in systemic mastocytosis. Leuk Res 2003 0.75
50 Pharmacotherapy of mast cell disorders. Curr Opin Allergy Clin Immunol 2017 0.75
51 Hymenoptera-induced anaphylaxis: is it a mast cell driven hematological disorder? Curr Opin Allergy Clin Immunol 2017 0.75
52 INTERACTIVE MEDICAL CASE. A Stinging Sensation. N Engl J Med 2015 0.75
53 Pre-emptive Evaluation of Venom Allergy in a Patient with Systemic Mastocytosis. Acta Derm Venereol 2017 0.75
54 Mast cell activation syndromes. Ann Allergy Asthma Immunol 2013 0.75